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Background: The lastly identified claudin-low (CL) subtype of breast cancer (BC) remains poorly described as
compared to the other molecular subtypes. We provide a comprehensive characterization of the largest series of CL
samples reported so far.
Methods: From a data set of 5447 invasive BC profiled using DNA microarrays, we identified 673 CL samples
(12,4%) that we describe comparatively to the other molecular subtypes at several levels: clinicopathological,
genomic, transcriptional, survival, and response to chemotherapy.
Results: CL samples display profiles different from other subtypes. For example, they differ from basal tumors
regarding the hormone receptor status, with a lower frequency of triple negative (TN) tumors (52% vs 76% for basal
cases). Like basal tumors, they show high genomic instability with many gains and losses. At the transcriptional
level, CL tumors are the most undifferentiated tumors along the mammary epithelial hierarchy. Compared to basal
tumors, they show enrichment for epithelial-to-mesenchymal transition markers, immune response genes, and
cancer stem cell–like features, and higher activity of estrogen receptor (ER), progesterone receptor (PR), EGFR, SRC
and TGFβ pathways, but lower activity of MYC and PI3K pathways. The 5-year disease-free survival of CL cases
(67%) and the rate of pathological complete response (pCR) to primary chemotherapy (32%) are close to those
of poor-prognosis and good responder subtypes (basal and ERBB2-enriched). However, the prognostic features
of CL tumors are closer to those observed in the whole BC series and in the luminal A subtype, including
proliferation-related gene expression signatures (GES). Immunity-related GES valuable in basal breast cancers are
not significant in CL tumors. By contrast, the GES predictive for pCR in CL tumors resemble more to those of
basal and HER2-enriched tumors than to those of luminal A tumors.
Conclusions: Many differences exist between CL and the other subtypes, notably basal. An unexpected finding
concerns the relatively high numbers of ER-positive and non-TN tumors within CL subtype, suggesting a larger
heterogeneity than in basal and luminal A subtypes.
Keywords: Breast cancer, Claudin-low, Molecular profiling, Prognosis, Response to chemotherapyBackground
Breast cancer (BC) is a heterogeneous disease with several
classification systems [1]. Molecular classification, based
on gene expression profiling, has been a major im-
provement of BC approach for a decade [2,3], with the
description of five major subtypes associated with different* Correspondence: bertuccif@ipc.unicancer.fr
1Department of Molecular Oncology, Centre de Recherche en Cancérologie
de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes (IPC), Marseille, France
2Department of Medical Oncology, Institut Paoli-Calmettes (IPC), Marseille,
France
Full list of author information is available at the end of the article
© 2014 Sabatier et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.molecular alterations and distinct clinical outcome
including therapeutic response: luminal A, luminal B,
ERBB2-enriched, basal and normal-like [2,4].
Following this discovery, additional subgroups of BC
were identified such as the interferon-enriched [5] and the
molecular apocrine [6] subgroups and several subgroups
of triple-negative BCs [7]. In 2007, a new intrinsic subtype
was described, the claudin-low subtype (CL), through the
combined analysis of murine mammary carcinoma models
and human BCs [8]. This subtype represented 6% of the
BC samples analyzed (13/232). Surprisingly, since then,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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characterization of CL BCs in a series of 76 and 32 cases,
respectively [9]. CL tumors lacked tight junction proteins
including claudin 3 and E-cadherin, and were character-
ized by a low expression of luminal markers and a high
expression of mesenchymal markers. Enriched in gene
expression signatures (GES) derived from human tumor-
initiating cells (TICs) and mammary stem cells [8], CL
tumors displayed the least differentiated phenotype along
the mammary epithelial differentiation hierarchy [9] and
were frequent in the residual mammary tumor tissue after
either hormone therapy or chemotherapy [10]. Today,
with less than 90 samples characterized, the CL subtype is
the least characterized subtype in the literature.
We analyzed more than 30 data sets containing almost
5500 clinically annotated BCs profiled using whole-genome
DNA microarrays and identified 673 CL samples. We
provide here a comprehensive characterization of CL
BCs at multiple levels: clinicopathological, genomic (DNA
copy number and mutations), transcriptional, survival,
response to chemotherapy, and analysis of prognostic and
predictive parameters.
Methods
Selection of the patients
We collected 32 retrospective data sets of BC samples
profiled using oligonucleotide microarrays (Additional
file 1: Table S1), including our own set (IPC set) and 31
public sets [3,6,9,11-39]. Regarding our own set, each
patient had given written informed consent and the
study had been approved by our institutional ethics
committee. Gene expression and clinicopathological data
of public series were retrieved from NCBI GEO and
Array Express databases and authors’ websites. The 32
data sets included a total of 5447 pre-treatment samples
of invasive adenocarcinoma.
Gene expression data pre-processing
Before analysis, we mapped hybridization probes across
the two technological oligonucleotide-based platforms
(Agilent and Affymetrix) used in these series. Affymetrix
gene chips annotations were updated using NetAffx Anno-
tation files (www.affymetrix.com; release from 01/12/2008).
Agilent gene chips annotations were retrieved and updated
using both SOURCE (http://smd.stanford.edu/cgi-bin/
source/sourceSearch) and EntrezGene (Homo sapiens
gene information db, release from 09/12/2008, http://
www.ncbi.nlm.nih.gov/gene/). All probes were thus
mapped based on their EntrezGeneID. When multiple
probes were mapped to the same GeneID, the one with
the highest variance in a particular dataset was selected
to represent the GeneID.
Data sets were then processed separately as follows. For
the Agilent-based sets, we applied quantile normalizationto available processed data. For the Affymetrix-based data
sets, we used Robust Multichip Average (RMA) [40] with
the non-parametric quantile algorithm as normalization
parameter. RMA was applied to the raw data from the
other series and the IPC series. Quantile normalization or
RMA was done in R using Bioconductor and associated
packages.
Gene expression data analysis
To avoid biases related to immunohistochemistry (IHC)
analyses across different institutions and to increase the
amount of available data, estrogen receptor (ER), proges-
terone receptor (PR) and ERBB2 expression analyses
were done at the mRNA level using gene expression data
of their respective gene, ESR1, PGR and ERBB2. Because
ESR1, PGR and ERBB2 expression profiles had bimodal
distribution, we identified a threshold of positivity, com-
mon to all sets, for each of these genes. Cases with gene
expression higher than this threshold were classified as
positive; the others were classified as negative [7].
Within each data set separately, the molecular subtypes
related to the intrinsic BC classification were determined
using the PAM50 classifier [41]. We first identified the
genes common between the 50-gene classifier and each
expression data set. Next, we used the expression centroid
of each subtype as defined by Parker and colleagues [41]
and measured the correlation of each sample with each
centroid. The sample was attributed the subtype corre-
sponding to the nearest centroid. To be comparable across
data sets and to exclude biases resulting from population
heterogeneity, expression data were standardized within
each data set. To identify CL samples, we used the
method described by Prat and colleagues [9]. Briefly, we
used the 808 genes from the nine-cell line CL predictor
to define the previously described “CL centroid” and
“non-CL centroid”, then calculated the Euclidean dis-
tance between each sample and each centroid, and
assigned the class of the nearest centroid. For non-CL
cases, we kept the subtype defined by the PAM50 classi-
fier. To compare the molecular characteristics of CL
BCs to those of the other subtypes, we used metagenes
and gene signatures associated with different biological
processes and pathways. We compared their expression
in CL tumors to that in the five other molecular subtypes.
We first developed, using an unsupervised approach, two
metagenes associated with the luminal and proliferation
patterns. They were established from the luminal and pro-
liferation gene clusters identified in the whole-genome
hierarchical clustering of 353 IPC samples: genes belong-
ing to these clusters had a correlation rate above 0.75 and
the two metagenes corresponded to the mean expression
of all genes included in each cluster. We also studied
metagenes associated with different immune popula-
tions [42]. Epithelial-to-mesenchymal transition (EMT)
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developed a core-EMT metagene defined as the Taube’s
Up/Down metagenes ratio. We also focused on previously
published GES of pathway activity [44]. Finally, because
CL BCs were described as having stem cell features, we
applied a differentiation predictor [9] derived from the
gene expression profiles of three mammary cell popu-
lations: mammary stem cells, luminal progenitors and
mature luminal cells [10,45]
We also tested the prognostic value of previously re-
ported classifiers associated with survival in BC: the
70-gene GES [11], the Genomic Grade Index (GGI)
[14], the Recurrence Score (RS) [46], the Risk of Relapse
(ROR) score [41], and the stroma-derived GES (B-cell
cluster) [47]. We also looked at the prognostic value of
signatures identified in ER-negative, triple negative or
basal BCs: the kinase immune metagene [48], the LCK
metagene [49], the immune response metagene [50]. Out
of these 8 prognosis signatures, 4 are rather related to cell
proliferation [11,14,41,46] and 4 to immunity [47-50]. Fi-
nally, we tested the predictive value of 4 multigene signa-
tures associated with pathological complete response
(pCR) after primary chemotherapy in BC: Diagonal
Linear Discriminant Analysis–30 predictor (DLDA30)
[18], A-score [21], stromal metagene [51], and RB-loss
signature [52].
Array-comparative genomic hybridization
We compared the genomic profile of CL tumors with
that of the other molecular subtypes by analyzing our
array-comparative genomic hybridization (aCGH) data-
base containing 256 BCs [53]. Data had been generated
by array-comparative genomic hybridization (aCGH)
using 244 K CGH Microarrays (Hu-244A, Agilent Tech-
nologies). Data analysis was done as previously described
[53]. Extraction of data (log2 ratio) was done from CGH
Analytics, whereas normalized and filtered log2 ratio was
obtained from “Feature Extraction” software (Agilent
Technologies). Frequencies of copy number alterations
of CL tumors were compared to that of all other breast
tumors using Fisher’s exact test with a 5% level of
significance. To identify chromosomal regions with a
statistically high frequency of copy number alterations
(CNAs), we used the GISTIC algorithm [54]. The
altered genes were compared to those described in CL
cases from a mouse model of P53null tumors [55]. We
also determined the genomic patterns of tumors using
Hicks’ classification [56].
Statistical analysis
Correlations between sample groups and clinicopathologi-
cal features were calculated with the Fisher’s exact test or
the Student’s t-test when appropriate. Disease-free survival
(DFS) was calculated from the date of diagnosis to thedate of first event (loco-regional or metastatic relapse,
death), and follow-up was measured to the date of last
news for event-free patients. Breast cancer patients with
metastasis at diagnosis were excluded from DFS analysis.
Survival curves were obtained using the Kaplan-Meier
method and compared with the log-rank test. Prognostic
analyses used the Cox regression method. Univariate
analyses tested classical clinicopathological features:
age, pathological tumor size (pT ≤ 20 mm vs >20), axillary
lymph node involvement (pN positive vs negative), SBR
grade (1 vs 2–3), ESR1, PGR and ERBB2 status (negative
versus positive), triple-negative status (yes versus no), and
pathological subtype. We also analyzed the pathological
response after neoadjuvant treatment which was available
in 6 public sets [18,19,23,25,34,39]. All statistical tests
were two-sided at the 5% level of significance. Analyses
were done using the survival package (version 2.30), in the
R software (version 2.15.2). Our analysis adhered to the
REporting recommendations for tumor MARKer prog-
nostic studies (REMARK) [57]. A Sweave report describ-
ing the analysis of gene expression data and the associated
statistical analysis has been generated and is available as
Additional file 2.
Results
Molecular subtypes
We collected public gene expression and clinicopatho-
logical data of a total of 5447 distinct invasive breast
carcinomas. We determined the molecular subtype of
tumors in each data set separately by using the PAM50
classifier [41] and the claudin-low predictor [9]: 1494
samples were luminal A (27.4%), 1077 (19.8%) were lu-
minal B, 749 (13.8%) were ERBB2-enriched, 1003 (18.4%)
were basal, 451 (8.2%) normal-like, and 673 (12.4%) were
CL. Seventy-eight percent of CL cases identified were ini-
tially attributed by the PAM50 classifier to the basal (53%)
and normal-like (25%) subtypes. Only 11% were luminal
A, 7% ERBB2-enriched and 4% luminal B.
For validation of the claudin-low predictor that we
applied, we compared our findings with those described
by Prat and colleagues in three data sets common with
ours [9,11,18] and found 98.5% of concordant classifi-
cation (Cl vs non-CL) out of the 337 tested samples
(332 samples accurately classified), with a specificity of
our predictor equal to 100% (all 32 CL samples according
to our predictor were CL according to Prat’s predictor)
and a sensitivity equal to 86% (5 out of 305 non-CL
samples according to our predictor were CL according
to Prat’s predictor).
Clinicopathological characteristics
Results, both descriptive and comparative, are shown in
Table 1. Each variable was compared between the CL
subtype and each of the other subtypes. Forty-nine
Table 1 Clinicopathological characteristics of invasive breast cancers according to the molecular subtypes
Variables N Claudin-low Luminal A Basal ERBB2-enriched Luminal B Normal-like
5447 673 1494 1003 749 1077 451
Age at diagnosis, years
<=50 1834 238(49%) 470(43%) 423(56%) 224(43%)* 328(46%)* 151(53%)*
>50 2005 247(51%) 622(57%) 331(44%) 291(57%) 380(54%) 134(47%)
Histological type
IDC 1181 140(78%) 263(76%) 224(88%) 201(89%) 255(89%) 98(84%)
ILC 72 8(4%) 34(10%) 4(2%) 4(2%) 12(4%) 10(9%)
MED 24 5(3%) 1(0%) 18(7%) 0(0%) 0(0%) 0(0%)
MIX 59 7(4%) 23(7%) 4(2%) 10(4%) 12(4%) 3(3%)
other 77 20(11%) 26(7%) 6(2%) 11(5%) 8(3%) 6(5%)
Histological grade
1 489 49(9%) 293(26%) 12(2%) 15(3%) 53(7%) 67(21%)
2 1579 180(35%) 605(54%) 104(14%) 170(32%) 367(47%) 153(48%)
3 1957 290(56%) 222(20%) 640(85%) 350(65%) 358(46%) 97(31%)
Pathological tumor size
pT1 928 106(38%) 343(46%) 130(29%) 89(27%) 163(34%) 97(50%)
pT2-3 1542 172(62%) 399(54%) 323(71%) 239(73%) 311(66%) 98(50%)
Pathological axillary lymph node status
negative 1907 180(54%) 550(61%) 379(65%) 232(51%)* 387(60%)* 179(59%)*
positive 1313 153(46%) 355(39%) 200(35%) 224(49%) 258(40%) 123(41%)
ESR1 expression status
negative 1929 433(64%) 80(5%) 859(86%) 437(58%) 24(2%) 96(21%)
positive 3518 240(36%) 1414(95%) 144(14%) 312(42%) 1053(98%) 355(79%)
ESR1 mRNA expression, median 5447 6.46 10.55 5.46 7.18 10.76 9.77
PGRexpression status
negative 2851 445(66%) 386(26%) 864(86%) 567(76%) 443(41%) 146(32%)
positive 2594 228(34%) 1108(74%) 139(14%) 181(24%) 634(59%) 304(68%)
PGR mRNA expression, median 5445 4.21 5.24 3.54 4.07 4.52 5.07
ERBB2 expression status
negative 4738 646(96%) 1407(94%)* 958(96%)* 320(43%) 1011(94%)* 396(88%)
positive 709 27(4%) 87(6%) 45(4%) 429(57%) 66(6%) 55(12%)
ERBB2 mRNA expression, median 5447 6.45 7.5 6.52 8.84 7.59 7.83
Triple-negative expression status
yes 1336 352(52%) 22(1%) 762(76%) 138(18%) 13(1%) 49(11%)
no 4110 321(48%) 1472(99%) 241(24%) 610(82%) 1064(99%) 402(89%)
Pathological complete response
pCR 302 73(32%) 21(7%) 104(33%)* 56(37%)* 40(18%) 8(14%)
RD 992 155(68%) 302(93%) 210(67%) 97(63%) 178(82%) 50(86%)
DFS event
no 2190 223(65%) 736(75%) 396(62%)* 222(52%) 395(60%)* 218(73%)*
yes 1165 120(35%) 246(25%) 245(38%) 205(48%) 268(40%) 81(27%)
5-year DFS [95CI] 3355 67% [0.62-0.73] 79% [0.77-0.83] 60% [0.56-0.64] 55% [0.5-0.6] 64% [0.6-0.68] 79% [0.75-0.84]
IDC: invasive ductal carcinoma; ILC: invasise lobular carcinoma; MED: medullary carcinoma; MIX: mixed; pCR: pathological complete response; RD: residual disease;
DFS: disease-free survival; OR: odd ratio; 95CI: 95% confidence interval.
*p-value < 0.05.
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younger. Patients with CL tumor were younger than those
with luminal A, ERBB2-enriched or luminal B tumors,
and older than patients with basal tumors. Most CL cases
were ductal carcinomas (78%). Other histological types
included lobular carcinomas (4%), carcinomas of mixed
histology (4%), and medullary carcinoma (3%). As ex-
pected, most of the metaplastic carcinomas were CL (5
out of 7: 71%). Histological grade of CL tumors was often
high (grade 3: 56%) or intermediate (grade 2: 35%), with
grade 1 observed in only 9% of cases. Differences with
the other subtypes were very significant with the basal
subtype, which contained more grade 3 samples, and
with the luminal A subtype, which contained less grade
3, and significant but to a lesser extent with the three
other subtypes (intermediate between ERBB2-enriched
and luminal B subtypes).
Thirty-eight percent of CL tumors measured 2 cm or
less (pT1), a percentage intermediate between that of
highly proliferative subtypes (basal, ERBB2-enriched, and
luminal B) and that of less proliferative ones (luminal A
and normal-like). Forty-six percent of CL samples pre-
sented pathological axillary lymph node involvement at
diagnosis. This ratio was significantly lower in basal
(35%) and luminal A (40%) samples. Most tumors (77%)
with lymph node involvement were larger than 2 cm.
However, the positive correlation between pT (pT1 vs
pT2-3) and the axillary lymph node status (negative vs
positive) was weaker in CL tumors (OR = 2.58) and basal
tumors (OR = 2.20) than in luminal A (OR = 3.60) or
normal-like (OR = 6.69) tumors.
Sixty-four percent and 66% of CL samples were classified
as negative for ESR1 and PGR respectively. As expected,
differences were highly significant when compared with the
two luminal and the normal-like subtypes, which were
much more frequently positive for ESR1 and PGR. A small
difference was observed with the ERBB2-enriched subtype.
More unexpected was the strong difference observed with
the basal subtype, which contained many more tumors
negative for ESR1 and PGR. Ninety-six percent of CL tu-
mors were negative for ERBB2, representing the highest
percentage among all subtypes. The difference was not
significant with the basal subtype, but significant with the
ERBB2-enriched and normal-like subtypes. Fifty-two
percent of CL tumors were triple negative (TN), sig-
nificantly less than basal tumors (76%) and more than
ERBB2-enriched samples (18%) and luminal A and B
samples (1% each). Twenty-seven percent of TN breast
cancers (TNBC) belonged to the CL subtype.
DNA copy number profiles
Most of the 28 CL samples profiled using aCGH displayed
several gains and losses suggesting a high genomic in-
stability. Because basal tumors are also known to be highlyinstable, we compared their genomic profile to those of
CL samples: no difference could be observed with many
gains and losses in both subtypes (Figure 1A). In the same
way, supervised analysis of CNAs between CL and non-
CL samples did not find any genomic region specifically
gained or lost in CL tumors. To identify the most gained
or lost regions, we used the GISTIC algorithm. Out of the
10 most gained regions we found 7p11.2 including EGFR,
17q12 (ERBB2), 17q21.32 (HOXB family), 4q13.3 (CXCL2,
3, 5 and 6), 11q13-q14 (PAK1) and 17q21.33 (MYST2,
PDK2). Some of the most lost regions were 8p23-p12
(DOK2, FGFR1), 4p16.3 (SPON2, FGFRL1), 17q21.2-q21.31
(STAT3) and 17p13.1-p12 (TP53, MAP2K4). Except TP53,
none of these genes were identified in aCGH analyses
performed on P53 null mice tumors [55].
Breast cancers can be classified in three classes accord-
ing to their genomic patterns [56]. Using this classifica-
tion, we observed 29%, 21% and 50% of simplex, firestorm
and sawtooth CL tumors, respectively. By comparing the
genomic patterns between molecular subtypes, we found
that CL samples displayed the smallest percentage of
firestorm profiles, the largest percentage of sawtooth
profiles, and a percentage of simplex profiles inter-
mediate between that of non-aggressive (luminal A and
normal-like) and aggressive (basal, ERBB2-enriched and lu-
minal B) subtypes. Based on these percentages, CL tumors
were different from ERBB2-enriched tumors (p = 4.45 E-04,
Fisher’s exact test) and luminal B tumors (p = 1.34 E-03)
with more complex sawtooth tumors (Additional file 3:
Table S2), whereas they were not different from basal BCs
(p = 0.24; Figure 1B).
Transcriptional profiles
We compared the mRNA expression of different genes
and pathways in CL versus other subtypes. As expected,
CL tumors showed low expression of ESR1, PGR and
ERBB2 genes (Table 1) and low expression of associated
genes as demonstrated by the low expression of the lu-
minal metagene (Figure 2) and the ER, PR and ERBB2 ac-
tivation pathways signatures (Additional file 4: Figure S1).
Regarding these genes and signatures, significant dif-
ferences existed between CL and the other subtypes,
including the basal subtype. CL BCs also differed from
basal BCs in other aspects. Expression of the proliferation-
related metagene in CL tumors was lower than in basal
tumors, but higher than in luminal A and normal-like
tumors (Figure 2 and Additional file 5: Table S3). CL
tumors displayed lower expression of MYC, PI3K, and
β-catenin activation pathways when compared to basal
cases, with activity levels close to those of luminal A
tumors for MYC and PI3K (Additional file 4: Figure S1).
By contrast, they showed higher expression than basal tu-
mors of EGFR, SRC, TGFβ and STAT3 activation pathways.
We also analyzed the expression of immune response GES
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Figure 1 Comparative genomic analysis of claudin-low and basal breast cancers. A) Frequency plots of DNA copy number alterations in
claudin-low samples (N = 28) and basal samples (N = 61). Frequencies (vertical axis, from 0 to 100%) are plotted as a function of chromosome
location (from 1pter on the left to 22qter on the right). Vertical lines indicate chromosome boundaries. Positive and negative values indicate
frequencies of tumors showing copy number increase and decrease, respectively, with gains (in red), amplifications (dark red), losses (in green)
and deletions (dark green). Bottom: supervised analysis comparing the genomic profiles of CL versus basal cases. The difference was assessed
with the Fisher’s exact test. The blue line indicates the limit of significance (p = 0.05). B) Genomic patterns of CL and basal tumors using Hicks’
classification [56]. The difference between the subtypes was assessed with the Pearson's Chi-squared test.
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ulocytes metagenes as compared to the other subtypes
(Figure 2). They also highly expressed the IFNγ activa-
tion pathway with similar level than that of basal cases
(Additional file 4: Figure S1).
We then focused on the expression of genes associated
with epithelial-to-mesenchymal transition (EMT). As
shown in Additional file 6: Figure S2, CL tumors dis-
played the lowest expression of genes coding for epi-
thelial cell-cell adhesion molecules (CDH1, claudin 3,
claudin 4, claudin 7 and occludin) and the highest ex-
pression of vimentin, SNAI1 and 2, TWIST1 and 2, and
ZEB1 and 2, known to be transcriptional repressors of
CDH1. This EMT pattern was confirmed using a GES
associated with EMT [43]: CL tumors had the highest
expression of the core-EMT metagene when compared
to the other subtypes (Figure 2).
Following the hypothesis that the molecular subtypes
are emerging at different stages of mammary cell differ-
entiation [45], we evaluated the differentiation degree ofCL tumors. Using a previously published differentiation
score [9], we observed that most of the CL cases (96%)
presented a score between those of mammary stem cells
and those of luminal progenitors (Figure 2). Only 4%
had a score close to those of mature luminal cells. This
pattern of differentiation was similar, although lightly
inferior, in basal tumors (92% between mammary stem
cells and luminal progenitors) and very different in the
other subtypes. Only 35% of ERBB2-enriched and nearly
15% of luminal samples had a low differentiation score
close the stem cell profile.
We then classified all samples according to a GES of
breast cancer stem cells (CD44+/CD24-/low-mammo-
spheres-forming cells) [10]. CL tumors were strongly
associated with the signature (Figure 2), suggesting enrich-
ment in stem cell features. Similarly, the expression of
gene markers of tumor-initiating cells (ALDH1A1, CD29,
INPP5D) was different between the CL subtype and the
other subtypes, including the basal subtype (data not
shown).
Figure 2 Comparison of gene expression signatures across molecular subtypes. Box plots of expression metagenes and scores across
molecular subtypes: luminal, proliferation, immune, and core-EMT metagenes, differentiation score (mL, mature luminal; pL, porogenitor luminal;
MaSC, mammary stem cells), stem cells score. P-values (t-test) of comparisons between CL and each of the other subtypes are shown as follows:
*, ≤5%; **, ≤1%; ***, ≤0.1%.
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Figure 3 DFS according to molecular subtypes. A) Frequencies of
relapses according to time from diagnosis between luminal A, basal and
CL breast cancers. B) Kaplan-Meier DFS curves in the 6 subtypes (p-value
for comparison between CL and basal tumors is shown, log-rank test).
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Clinical outcome was available for 3682 out of 5447
patients with 5-year DFS rate equal to 67% (CI95, 66–69),
including 343 out of 673 with CL BC. In the CL subtype,
the median follow-up was 72 months for the 251 event-
free patients. A total of 130 patients (34%) displayed a
DFS event. Similarly to the basal subtype (and differently
from the luminal A subtype), most of the relapses oc-
curred in the first three years (Figure 3A), with median
times to relapse of 19 months and 17 months for CL
and basal tumors, respectively. The 5-year DFS rate
was 67% (CI95, 62–73; N = 343) in the CL subtype
(Figure 3B), intermediate between that observed in
ERBB2-enriched BC patients (55% 5-year DFS, p = 2.3
E-03, log-rank test; N = 426) and luminal A BC patients
(79% 5-year DFS, p = 6.7 E-07, log-rank test; N = 982) and
normal-like BC patients (79% 5-year DFS, p = 4.7 E-04,
log-rank test; N = 299). The prognosis of CL cases was not
different from that of luminal B samples (64% 5-year DFS;
p = 0.56, log-rank test; N = 663), and was better although
not significantly different from that of basal tumors (60%
5-year DFS rate; p = 0.11, log-rank test; N = 641). Unfortu-
nately, the site of first metastatic relapse was not informed
in most of the cases studied.
We then performed prognostic analyses in the CL
subtype by assessing the prognostic impact of the usual
clinicopathological features. In univariate analysis, the
well-known unfavorable clinicopathological features
(pT > 2 cm, grade 2–3, pN-positive, low ESR1 expression,
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associated with shorter DFS in patients with CL tumor
(Table 2). Comparison with the results observed in the
whole BC series and in each of the other subtype
(Additional file 7: Table S4) revealed that the prognostic
features were the same in the CL subtype and in the whole
series, totally different between the CL and the other pro-
liferative subtypes (basal, ERBB2-enriched and luminal B).
The largest similarity was observed with the luminal A
subtype.
We also compared the prognostic value of 8 prognostic
GES in the different subtypes (Table 2 and Additional
file 7: Table S4). Whereas 6 signatures (4 proliferation-
related and 2 immunity-related) showed prognostic value
in the whole series of samples, only two conserved their
prognostic value in CL tumors (Table 2): the RS (HR = 3
when comparing high risk to low risk cases, p = 1.1 E-03)
and the ROR (HR = 1.85, p = 8.7E-04). There was a trend
for the B-cell cluster (HR = 1.6 when comparing poor
vs good-prognosis groups cases, p = 0.07). The 2 otherTable 2 Univariate Cox regression analysis for DFS
A. Clinicopathological features Claudi
n
Age at diagnosis, years >50 vs ≤50 237
Histological type ILC vs IDC 59
MED vs IDC
MIX vs IDC
other vs IDC
Histological grade 2-3 vs 1 270
Pathological tumor size pT2-3 vs pT1 155
Pathological axillary lymph node status positive vs negative 194
ESR1 expression status positive vs negative 343
PGR expression status positive vs negative 343
ERBB2 expression status positive vs negative 343
Triple-negative expression status yes vs no 343
B. Gene expression signatures
70-gene GES [11] Poor vs Good 343
GGI [14] Poor vs Good 283
RS [46] Intermediary vs Good 343
Poor vs Good
ROR [41] Intermediary vs Good 343
Poor vs Good
Immune response metagene [50] Poor vs Good 343
LCK metagene [49] Poor vs Good 343
Kinase immune metagene [48] Poor vs Good 343
B-cell cluster [47] Intermediary vs Good 343
Poor vs Good
IDC: invasive ductal carcinoma; ILC: invasise lobular carcinoma; MED: medullary carc
P-values < 0.05 are represented in boldface.proliferation-related signatures (70-gene GES and GGI)
and the 3 other immunity-related signatures (immune
response, LCK, and kinase immune metagenes) had no
prognostic value in the CL population. By contrast,
the results were very different in the other subtypes
(Additional file 7: Table S4). For example, most of the
immunity-related signatures were significant in the
basal and ERBB2-enriched subtypes, whereas none of
the proliferation-related classifiers had a prognostic
value in this population in contrast with the luminal A
subtype. Results were also different in the luminal B
subtype, where 3 proliferation-related and 2 immunity-
related signatures showed prognostic value. Altogether,
these results suggest that CL tumors have different prog-
nostic features than the other subtypes.
Pathological response to chemotherapy and predictive
features
Pathological response to neoadjuvant chemotherapy was
available for 1294 patients out of 5447 patients with an-Low All samples
HR [95CI] p-value n HR [95CI] p-value
0.9 [0.57-1.4] 0.636 2366 1.01 [0.87-1.16] 0.923
0.00 [0.00- Inf] 0.837 624 1.09 [0.71-1.67] 0.269
0.45 [0.06-3.35] 0.53 [0.20-1.42]
0.00 [0.00- Inf] 0.44 [0.18-1.06]
1.90 [0.44-8.10] 1.04 [0.57-1.92]
3.63 [1.32-9.92] 1.22E-02 2552 2.36 [1.86-3.01] 2.84E-12
2.33 [1.27-4.26] 6.01E-03 1744 1.52 [1.29-1.8] 6.83E-07
2.23 [1.34-3.72] 2.01E-03 2365 1.45 [1.26-1.68] 3.95E-07
0.38 [0.25-0.58] 5.02E-06 3355 0.56 [0.5-0.63] <2.0E-16
0.56 [0.38-0.83] 3.86E-03 3353 0.7 [0.63-0.79] 2.24E-09
1.98 [0.92-4.26] 0.079 3355 1.4 [1.18-1.65] 7.22E-05
2.19 [1.51-3.18] 3.82E-05 3354 1.7 [1.49-1.94] 1.22E-15
1.22 [0.74-2.02] 0.435 3355 1.83 [1.57-2.12] 3.00E-15
1.42 [0.92-2.2] 0.113 2655 2.1 [1.82-2.43] <2.0E-16
2.73 [1.40-5.31] 1.09E-03 3355 1.63 [1.38-1.93] <2.0E-16
3.03 [1.68-5.46] 2.15 [1.87-2.47]
1.28 [0.69-2.36] 8.74E-03 3355 1.75 [1.45-2.10] <2.0E-16
1.85 [1.24-2.75] 2.11 [1.85-2.41]
1.17 [0.82-1.68] 0.387 3354 1.19 [1.06-1.34] 2.93E-03
1.12 [0.78-1.6] 0.541 3355 1.1 [0.96-1.26] 0.152
1.14 [0.78-1.65] 0.507 3355 1.04 [0.88-1.24] 0.615
1.15 [0.74-1.79] 0.0692 3353 1.20 [1.04-1.38] 3.94E-05
1.64 [1.07-2.52] 1.38 [1.20-1.59]
inoma; MIX: mixed; HR: hazard ratio; 95CI: 95% confidence interval.
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data available, the pCR rate was 32% (Table 1), higher than
in luminal A (7%, p < E-04, Fisher’s exact test; N = 323), lu-
minal B (18%, p = 1.1 E-03; N = 218), and normal-like tu-
mors (14%, p = 5.4 E-03; N = 58), and similar to the rate
observed in basal (33%, p = 0.85; N = 314) and ERBB2-
enriched cases (37%, p = 0.38; N = 153).
Analysis of predictive value of clinicopathological
features in CL tumors (Table 3) showed that pCR rates
tended to be higher in high grade tumors (p = 0.06,
Fisher’s exact test) and in samples with low ESR1 expres-
sion (p = 0.07). By contrast (Additional file 8: Table S5),
ESR1 expression level did not tend to have predictive
value in the basal and ERBB2-enriched subtypes. We
also tested the predictive value of 4 GES published as
predictive of pathological response in breast cancer
treated by anthracycline-based chemotherapy. Only
two were associated with pCR in CL tumors: the
DLDA30 predictor (p = 1.6 E-02, Fisher’s exact test),
and the A-score (p = 3.2 E-03), which also predicted
pCR in the basal and ERBB2-enriched subtypes. By
contrast, the stromal metagene and the RB-loss signature
failed to predict pCR in CL tumors, whereas they pre-
dicted pCR in basal and ERBB2-enriched cancers, re-
spectively. Finally, 3 out of 4 signatures were associated
with pCR in the whole series of 1294 samples.
Discussion
We provide a comprehensive characterization of a series
of 673 CL BCs collected though a meta-analysis of
public gene expression data. This represents the largest
series reported so far in the literature, with nearly 9-fold
more samples than in the pioneering study [9]. We de-
fined the CL breast tumors using the published cell line-
based CL predictor [9], which in our hands gave a very
high degree of concordance (98.5%) with the predictor
originally reported in a common set of 337 samples,
suggesting that the CL subtype that we define here
overlaps the CL subtype originally described. The sub-
type of non-CL samples was defined using the classical
PAM50 classifier [41]. Using these standard classifiers,
we observed the expected incidence of each subtype.
The incidence of CL tumors was 12.4%, similar to the 7
to 14% incidence reported by Prat and colleagues in 3
distinct small databases [9]. In our analysis, the PAM50
classifier attributed most of the current CL tumors to the
basal and normal-like subtypes (53% and 25%, respect-
ively) as previously described [9]. The large number of
samples in each subtype provided an unprecedented op-
portunity to describe the characteristics of CL tumors and
to perform prognostic and predictive analyses specifically
in this subtype, comparatively with the other subtypes.
Also for the first time, we present genomic data of human
CL tumors.Only one published study [9] has described so far the
clinicopathological characteristics of CL samples, but in-
formation was relatively limited: pathological size, grade,
axillary lymph node status and IHC ER status were avail-
able for 76 cases, and PR and ERBB2 status for 55 cases.
Our percentages of CL tumors with pT2-T3 size (62%),
with pN- status (54%) and with grade 3 (56%) are close
to those reported by Prat (65%, 47% and 62% respect-
ively). Differences are more important and thus unex-
pected regarding the hormone receptors and ERBB2
status. In Prat’s study, 79%, 77% and 84% of CL samples
were IHC ER-negative (out of 71 informative samples
tested at the protein level with IHC), PR-negative (out of
40 informative samples) and ERBB2-negative (out of 45
informative samples) respectively, versus 64%, 66% and
96% in our transcriptional analysis, respectively (Figure 4).
Similarly, the percentage of IHC TN samples was 67% in
Prat’s study (out of 39 informative samples) versus 52% in
ours (out of 673 samples tested at the mRNA level with
DNA microarrays). These discordances may be due to
various reasons. The first one may be the difference of
technology used to define the ER, PR, ERBB2 and TN
status (IHC versus mRNA expression profile), even if
differences are known to be limited [58]. Thanks to the
simultaneous availability of IHC ER, PR and ERBB2
status for 2259 breast cancer samples of our pooled
series, including 294 CL samples, we could redefine the
TN status at the protein level as did Prat and colleagues.
We found results similar or very close to those observed
at the mRNA level in the whole series of 673 samples:
52% of CL samples were TN, 63% were ER-negative,
68% were PR-negative and 89% were ERBB2-negative,
versus 52% 64%, 66% and 96% respectively in our tran-
scriptional analysis. Of note, the results remained
exactly the same after exclusion of the Prat’s samples.
The second and likely main reason for discrepancy lies
in the large quantitative difference in series analyzed: we
defined the ER and TN status of CL samples in a series
of 673 samples, whereas Prat et al. defined the ER status
on three small series of 32 (UNC337), 21 samples
(NKI295) and 18 samples (MDACC), and the TN status
on two small series of 21 (UNC337) and 18 samples
(MDACC) with relative large variations across series
regarding the percentage of ER-negative cases (from
67 to 88%) and TN cases (from 61 to 71%). Prat and
colleagues did not compare statistically the clinicopatho-
logical features of the CL subtype with those of the other
subtypes, likely because of the series size limitation. In our
analysis, CL BCs displayed only one feature common with
basal tumors (ERBB2 status), whereas differences were
significant regarding all the other features: age at diagnosis
(less young patients in CL cases), pathological type (less
often ductal or medullary, but more often metaplastic in
CL), grade (less often grade 3 in CL), tumor size (less
Table 3 Univariate Fisher’s exact test analysis for pathological complete response according to clinicopathological and
molecular features
A. Clinicopathological
features
Claudin-low All samples
N RD pCR p-value* OR [95CI] N RD pCR p-value* OR [95CI]
Age at diagnosis, years 0.392 0.76 0.09 0.8
≤50 123 80 (52%) 43 (59%) [0.41-1.37] 697 521 (53%) 176 (58%) [0.61-1.04]
>50 104 74 (48%) 30 (41%) 595 469 (47%) 126 (42%)
Pathological tumor size 1.00 0.93 0.859 1.1
pT1 5 3 (8%) 2 (9%) [0.1-11.96] 44 32 (14%) 12 (13%) [0.53-2.53]
pT2-3 55 34 (92%) 21 (91%) 279 196 (86%) 83 (87%)
Histological grade 0.06 Inf 1.68E-04 8.1
1 8 8 (6%) 0 (0%) [0.82-Inf] 53 51 (6%) 2 (1%) [2.11-69.38]
2-3 204 136 (94%) 68 (100%) 1126 854 (94%) 272 (99%)
Histological type 0.125 0.75
IDC 77 45 (67%) 32 (84%) 468 337 (82%) 131 (85%)
ILC 5 3 (4%) 2 (5%) 15 10 (2%) 5 (3%)
MIX 6 6 (9%) 0 (0%) 37 29 (7%) 8 (5%)
other 17 13 (19%) 4 (11%) 47 36 (9%) 11 (7%)
ESR1 expression status 0.07 0.47 7.21E-18 0.3
negative 183 119 (77%) 64 (88%) [0.19-1.07] 697 470 (47%) 227 (75%) [0.22-0.4]
positive 45 36 (23%) 9 (12%) 597 522 (53%) 75 (25%)
PGRexpression status 0.42 0.64 4.24E-08 0.38
negative 195 130 (84%) 65 (89%) [0.24-1.57] 979 716 (72%) 263 (87%) [0.26-0.56]
positive 33 25 (16%) 8 (11%) 315 276 (28%) 39 (13%)
ERBB2 expression status 0.472 1.7 5.90E-04 1.9
negative 219 150 (97%) 69 (95%) [0.33-8.34] 1125 881 (89%) 244 (81%) [1.31-2.7]
positive 9 5 (3%) 4 (5%) 169 111 (11%) 58 (19%)
Triple-negative expression status 0.285 1.4 8.16E-10 2.3
no 71 52 (34%) 19 (26%) [0.74-2.83] 777 642 (65%) 135 (45%) [1.73-2.97]
yes 157 103 (66%) 54 (74%) 517 350 (35%) 167 (55%)
DLDA30 [18] 1.61E-02 0.49 7.53E-23 0.26
pCR-like 120 73 (47%) 47 (64%) [0.27-0.91] 439 264 (27%) 175 (58%) [0.2-0.35]
RD-like 108 82 (53%) 26 (36%) 855 728 (73%) 127 (42%)
Stromal metagene [51] 0.623 1.2 0.12 0.81
pCR-like 55 39 (25%) 16 (22%) [0.59-2.5] 642 480 (48%) 162 (54%) [0.62-1.06]
RD-like 173 116 (75%) 57 (78%) 652 512 (52%) 140 (46%)
A-score [21] 3.15E-03 3.9 1.48E-04 2
RD-like 37 31 (32%) 6 (11%) [1.46-12.32] 258 196 (46%) 62 (30%) [1.36-2.85]
pCR_Like 118 67 (68%) 51 (89%) 378 233 (54%) 145 (70%)
RB-loss signature [52] 1.00 0.96 6.52-03 1.7
Low (RD-like) 212 144 (93%) 68 (93%) [0.25-3.15] 1150 895 (90%) 255 (84%) [1.14-2.51]
High (pCR-like) 16 11 (7%) 5 (7%) 144 97 (10%) 47 (16%)
*, Fisher’s exact test.
IDC: invasive ductal carcinoma; ILC: invasise lobular carcinoma; MIX: mixed; pCR: pathological complete response; RD: residual disease; OR: odds ratio; 95CI: 95%
confidence interval.
P-values < 0.05 are represented in boldface.
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A B
Figure 4 Radar charts comparing clinicopathological, genomic and transcriptional features through the 6 main molecular subtypes.
Each axis of the diagrams represents a scale of proportions for a specific feature, ranging from 0% to 100%. The proportion of a given feature in a
given molecular subtype is reported on the corresponding axis. A) Clinicopathological features. B) Probabilities of pathway activation calculated
according to [44].
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tive in CL), ER and PR status (less often negative in CL),
and triple-negative status (less frequent in CL).
To our knowledge, the genomic profiles of CL tumors
have been reported only in two studies that described
the CNA patterns of a total of 5 CL murine p53-null
tumors [8,55]. Based on the analysis of 28 samples, we
showed that CL tumors have a high genomic instability
with many gains and losses, frequent complex sawtooth
patterns, and the smallest percentage of firestorm profiles.
This profile is close to what has been already published
concerning basal cases [53], and no significant difference
could be identified with basal tumors. It is of note that the
main regions we identified as gained or lost in CL samples
were not described in genomic analyses of previously pub-
lished murine models [55]. This suggests that, like for the
basal subtype, CL tumorigenesis may be driven by several
oncogenic events, and not by a single driver as it can be
observed in ERBB2-enriched tumors [59].
At the transcriptional level, we found that the CL
subtype differs from the other subtypes in many aspects
(Figure 4). We confirmed that CL tumors lack luminal
differentiation markers, and show enrichment for EMT
markers, immune response genes, and cancer stem
cell–like features. They also have a relative low expres-
sion of the P53 pathway suggesting apoptosis inhib-
ition. They differ from basal BC at several levels. Both
have lower expression of ESR1, PGR, ERBB2 genes and
ER, PR and ERBB2 activation pathways than the other
subtypes, but the expression of ER and PR genes and
pathways is higher in CL tumors than in basal tumors.
CL BCs are also less proliferative than basal cancers. They
overexpress genes associated with immune response andstroma and have higher expression of EMT-related genes
and signatures, thus confirming previous results. We also
confirmed that CL tumors are the most undifferentiated
ones at the molecular level along the normal mammary
epithelial differentiation hierarchy (differentiation score
close the stem cell profile) and are the most enriched in
stem cell features, followed by basal tumors. CL and basal
tumors are also distinguished by the expression of several
pathway activation signatures; for examples, basal cancers
displayed higher activity of MYC and PI3K pathways as
already reported [60,61], whereas CL tumors showed
higher activity of EGFR, SRC and TGFβ pathways as
reported by others [7] with therapeutic possibilities.
Regarding prognosis, the DFS, available for 343 patients
with CL BC, was poor with 67% 5-year DFS, close to that
reported by Prat and colleagues in their 58-patients series
[9]. Compared with the other subtypes, the 5-year DFS
was inferior to that observed in the two good-prognosis
subtypes (luminal A and normal-like), similar to that ob-
served in the luminal B subtype, and tended to be better
than that observed in the two other poor-prognosis sub-
types (basal and ERBB2-enriched), even if the difference
(7%) with basal tumors was not significant. The earlier
timing of relapse compared with the luminal A subtype,
similarly to that observed in the basal subtype, agreed with
the proliferative nature of CL tumors. It is now recognized
that the prognostic features are somewhat different be-
tween the different subtypes [62,63]. This has never
been explored to date in CL BCs. Most of the clinico-
pathological prognostic variables tested in CL samples
were significant (pT, grade, pN, ESR1 and PGR expres-
sion), as observed in the whole series and the luminal A
subtype. Unexpectedly, in term of prognostic features, the
Sabatier et al. Molecular Cancer 2014, 13:228 Page 12 of 14
http://www.molecular-cancer.com/content/13/1/228subtype most different from CL was the basal subtype,
and the most similar was the luminal A subtype, the less
proliferative one. We also analyzed the prognostic value of
8 published signatures, 4 related to cell proliferation,
known to be strongly prognostic in ER-positive samples,
and 4 to immunity, known to be strongly prognostic in
ER-negative samples. Similarly to the results observed
with the clinicopathological variables, proliferation-related
classifiers useful to predict luminal A tumors prognosis
had (or tended to have) a prognostic value in CL samples,
whereas immunity-related GES, described to be relevant
in basal and HER2-enriched BCs, did not.
The profile of chemosensitivity of CL tumors was
assessed in 228 cases. The pCR rate after neoadjuvant
chemotherapy was close (32%) to that of basal (33%)
and ERBB2-enriched tumors (37%), and significantly
higher than the rates observed for luminal A (7%), luminal
B (18%), and normal-like tumors (14%). Similar obser-
vations have been reported by Prat and colleagues [9]
in a smaller series of 133 samples including 18 CL,
with higher pCR rates in the CL (39%), basal (79%) and
ERBB2-enriched (39%) cases. As discussed above with
the prognostic features, the clinicopathological features
predictive for pCR in the CL subtype (grade and ESR1
status) were predictive in the whole series of samples
and the luminal A subtype, but were not predictive in
the ER-negative subtypes (basal and ERBB2-enriched).
The predictive value of 4 previously published predictive
GES was also different between CL and the other subtypes.
Conclusions
In conclusion, we revealed many differences between CL
and the other molecular subtype of breast cancers, notably
the basal subtype. Differences are present at all tested
levels, including the molecular and clinicopathological
characteristics, the clinical outcome and the prognostic
features. The strength of our study lies in both its com-
prehensiveness and the number of samples analyzed.
Limitations are those of any retrospective multicenter
study, including potential selection bias and the un-
availability of certain clinicopathological variables. Our
results suggest that CL tumors represent a different
subtype. They also reveal some unexpected findings
that warrant further study to better understand this yet
mysterious subtype. The most important ones concern
the relatively high numbers of ER-positive tumors and
non-TN tumors within the CL subtype: 36% and 48%
respectively versus only 14% and 24% in the basal sub-
type and 95% and 99% in the luminal A subtype. This
difference in a major feature of breast cancer (ER status)
suggests that the so-defined CL subtype is much more
heterogeneous than basal and luminal A subtypes. Such
a mixture of ER-negative and ER-positive samples likely
explains the intermediate/mixed pattern of CL subtypebetween the basal and the luminal A subtypes in terms of
clinicopathological and molecular characteristics, survival,
prognostic features, and response to chemotherapy.Additional files
Additional file 1: Table S1. Description of the 32 breast cancer data sets.
Additional file 2: Sweave report of gene expression data and
associated statistics.
Additional file 3: Table S2. Genomic patterns of the molecular
subtypes using the Hicks’ classification [56].
Additional file 4: Figure S1. Comparison of probabilities of pathway
activation across molecular subtypes. Box plots of probabilities of activation
of 12 pathways from [44]. P-values (t-test) of comparisons between CL and
each of the other subtypes are shown as follows: *, ≤5%; **, ≤1%; ***,
≤0.1%.
Additional file 5: Table S3. Odd ratios and p-values of comparison of
gene expression signatures across molecular subtypes.
Additional file 6: Figure S2. Comparison of mRNA expression levels of
genes associated with EMT across molecular subtypes. Expression values
are log2-scaled. P-values (t-test) of comparisons between CL and each of
the other subtypes are shown as follows: *, ≤5%; **, ≤1%; ***, ≤0.1%.
Additional file 7: Table S4. Univariate Cox regression analysis for DFS
in all subtypes.
Additional file 8: Table S5. Univariate analysis for pathological
complete response according to clinicopathological and molecular
features in all subtypes.Abbreviations
CL: Claudin-low; BC: Breast cancer; EMT: Epithelial to mesenchymal
transition; ER: Estrogen receptor; PR: Progesterone receptor; DFS:
Disease-free survival; pCR: Pathological complete response; GES: Gene
expression signature; TN: Triple-negative; RMA: Robust multichip average;
IHC: Immunohistochemistry; IPC: Institut Paoli-Calmettes; GGI: Genomic
grade index; RS: Recurrence score; ROR: Risk of relapse; DLDA-30: Diagonal
Linear Discriminant Analysis–30; CGH: Comparative genomic hybridization;
CNA: Copy number alterations.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RS and FB designed the concept of the study. FB, RS and PV were
responsible for provision of study patients. RS and PF were responsible for
samples and data gathering, nucleic acids extraction and microarray
experiments. JA, AG and MC were responsible for array-CGH experiments,
and analysis. RS, PF and FB were responsible for statistical analysis and final
interpretation. RS, FB and DB wrote the final manuscript. All authors read and
approved the final manuscript.
Acknowledgements
Our work is supported by the Institut National du Cancer (INCa) Translational
Research Grant 2007 (FB), Translational Research Grant 2009 (DB) and
Biologic Research Grant 2010 « IVOIRES » (FB), the Ligue Nationale Contre le
Cancer (label DB) and SIRIC (INCa-DGOS-Inserm 6038 grant).
Author details
1Department of Molecular Oncology, Centre de Recherche en Cancérologie
de Marseille, UMR1068 Inserm, Institut Paoli-Calmettes (IPC), Marseille, France.
2Department of Medical Oncology, Institut Paoli-Calmettes (IPC), Marseille,
France. 3Faculté de Médecine, Université Aix-Marseille, Marseille, France.
Received: 8 April 2014 Accepted: 22 September 2014
Published: 2 October 2014
Sabatier et al. Molecular Cancer 2014, 13:228 Page 13 of 14
http://www.molecular-cancer.com/content/13/1/228References
1. Viale G: The current state of breast cancer classification. Ann Oncol 2012,
23(Suppl 10):x207–x210.
2. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406:747–752.
3. Veer LJ V’t, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse
HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven
RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression
profiling predicts clinical outcome of breast cancer. Nature 2002,
415:530–536.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen
MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO,
Botstein D, Lønning PE, Børresen-Dale AL: Gene expression patterns of
breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci U S A 2001, 98:10869–10874.
5. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA,
Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y,
Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L,
Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade
OI, Bernard PS, et al.: The molecular portraits of breast tumors are
conserved across microarray platforms. BMC Genomics 2006, 7:96.
6. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D,
Macgrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz A-L,
Brisken C, Fiche M, Delorenzi M, Iggo R: Identification of molecular apocrine
breast tumours by microarray analysis. Oncogene 2005, 24:4660–4671.
7. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y,
Pietenpol JA: Identification of human triple-negative breast cancer
subtypes and preclinical models for selection of targeted therapies.
J Clin Invest 2011, 121:2750–2767.
8. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, Rasmussen
KE, Jones LP, Assefnia S, Chandrasekharan S, Backlund MG, Yin Y, Khramtsov
AI, Bastein R, Quackenbush J, Glazer RI, Brown PH, Green JE, Kopelovich L,
Furth PA, Palazzo JP, Olopade OI, Bernard PS, Churchill GA, Van Dyke T,
Perou CM: Identification of conserved gene expression features between
murine mammary carcinoma models and human breast tumors. Genome
Biol 2007, 8:R76.
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou
CM: Phenotypic and molecular characterization of the claudin-low
intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68.
10. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm
DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A,
Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM,
Lewis MT, Rosen JM, Chang JC: Residual breast cancers after conventional
therapy display mesenchymal as well as tumor-initiating features. Proc
Natl Acad Sci U S A 2009, 106:13820–13825.
11. Van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AAM, Voskuil DW, Schreiber
GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A,
Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH,
Bernards R: A gene-expression signature as a predictor of survival in breast
cancer. N Engl J Med 2002, 347:1999–2009.
12. Schmidt M, Böhm D, von Törne C, Steiner E, Puhl A, Pilch H, Lehr H-A,
Hengstler JG, Kölbl H, Gehrmann M: The humoral immune system has a
key prognostic impact in node-negative breast cancer. Cancer Res 2008,
68:5405–5413.
13. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D,
Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D,
Foekens JA: Gene-expression profiles to predict distant metastasis of
lymph-node-negative primary breast cancer. Lancet 2005, 365:671–679.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz
V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse
M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M: Gene
expression profiling in breast cancer: understanding the molecular basis of
histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262–272.
15. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan
Y, Hall P, Nordgren H, Wong JEL, Liu ET, Bergh J, Kuznetsov VA, Miller LD:
Genetic reclassification of histologic grade delineates new clinical
subtypes of breast cancer. Cancer Res 2006, 66:10292–10301.
16. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d’ Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL,Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong
time dependence of the 76-gene prognostic signature for node-negative
breast cancer patients in the TRANSBIG multicenter independent validation
series. Clin Cancer Res 2007, 13:3207–3214.
17. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P,
Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human
breast cancer predicts mutation status, transcriptional effects, and
patient survival. Proc Natl Acad Sci U S A 2005, 102:13550–13555.
18. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser
D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS,
Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L: Pharmacogenomic
predictor of sensitivity to preoperative chemotherapy with paclitaxel
and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
J Clin Oncol 2006, 24:4236–4244.
19. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M,
Petit T, Rouanet P, Jassem J, Blot E, Becette V, Farmer P, André S, Acharya
CR, Mukherjee S, Cameron D, Bergh J, Nevins JR, Iggo RD: Validation of gene
signatures that predict the response of breast cancer to neoadjuvant
chemotherapy: a substudy of the EORTC 10994/BIG 00–01 clinical trial.
Lancet Oncol 2007, 8:1071–1078.
20. Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan
G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F, Bonnet F, Martin
AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci
F, de Thé H, Theillet C: A refined molecular taxonomy of breast cancer.
Oncogene 2012, 31:1196–1206.
21. Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags
J, Delaloge S, Duhem C, Kains J-P, Carly B, Maerevoet M, Vindevoghel A,
Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R, Bontempi
G, Michiels S, Buyse M, Nogaret J-M, Qi Y, Symmans F, Pusztai L, D’Hondt V,
Piccart-Gebhart M, Sotiriou C: Multifactorial approach to predicting resist-
ance to anthracyclines. J Clin Oncol 2011, 29:1578–1586.
22. Expression Project for Oncology. [http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE2109]
23. Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker
JS, Swain SM, Hunter K, Zujewski JA: Gene expression pathway analysis to
predict response to neoadjuvant docetaxel and capecitabine for breast
cancer. Breast Cancer Res Treat 2010, 119:685–699.
24. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB,
Gerald WL, Massagué J: Genes that mediate breast cancer metastasis to
lung. Nature 2005, 436:518–524.
25. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray J, Murray
E, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM: Changes in
breast cancer transcriptional profiles after treatment with the aromatase
inhibitor, letrozole. Pharmacogenet Genomics 2007, 17:813–826.
26. Klein A, Wessel R, Graessmann M, Jürgens M, Petersen I, Schmutzler R,
Niederacher D, Arnold N, Meindl A, Scherneck S, Seitz S, Graessmann A:
Comparison of gene expression data from human and mouse breast
cancers: identification of a conserved breast tumor gene set. Int J Cancer
2007, 121:683–688.
27. Hoeflich KP, O’Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T,
Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin
M, Friedman LS, Lackner MR: In vivo antitumor activity of MEK and
phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer
models. Clin Cancer Res 2009, 15:4649–4664.
28. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot
I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC,
Stern M-H, Thiery J-P, Hickman JA, Dubois T: Frequent PTEN genomic
alterations and activated phosphatidylinositol 3-kinase pathway in
basal-like breast cancer cells. Breast Cancer Res 2008, 10:R101.
29. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo W-L, Lapuk A,
Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S,
Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Wald-
man FM, Gray JW: Genomic and transcriptional aberrations linked to breast
cancer pathophysiologies. Cancer Cell 2006, 10:529–541.
30. Yu K, Ganesan K, Tan LK, Laban M, Wu J, Zhao XD, Li H, Leung CHW, Zhu Y,
Wei CL, Hooi SC, Miller L, Tan P: A precisely regulated gene expression
cassette potently modulates metastasis and survival in multiple solid
cancers. PLoS Genet 2008, 4:e1000129.
31. Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van
de Vijver MJ, Gerald WL, Foekens JA, Massagué J: Genes that mediate
breast cancer metastasis to the brain. Nature 2009, 459:1005–1009.
Sabatier et al. Molecular Cancer 2014, 13:228 Page 14 of 14
http://www.molecular-cancer.com/content/13/1/22832. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck
N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FCGJ,
Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA: The
76-gene signature defines high-risk patients that benefit from adjuvant
tamoxifen therapy. Breast Cancer Res Treat 2009, 116:303–309.
33. Barry WT, Kernagis DN, Dressman HK, Griffis RJ, Hunter JD, Olson JA, Marks
JR, Ginsburg GS, Marcom PK, Nevins JR, Geradts J, Datto MB: Intratumor
heterogeneity and precision of microarray-based predictors of breast
cancer biology and clinical outcome. J Clin Oncol 2010, 28:2198–2206.
34. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong
C-O, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De
Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber
JE: Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
J Clin Oncol 2010, 28:1145–1153.
35. Chen D-T, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T,
Agrawal D, McCarthy SM, Gruidl M, Bloom G, Anderson T, White J,
Quackenbush J, Yeatman T: Proliferative genes dominate malignancy-risk
gene signature in histologically-normal breast tissue. Breast Cancer Res Treat
2010, 119:335–346.
36. Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y,
Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi
M, Hortobagyi GN, Shi L, Symmans WF, Pusztai L: Effect of training-sample
size and classification difficulty on the accuracy of genomic predictors.
Breast Cancer Res 2010, 12:R5.
37. Iwamoto T, Bianchini G, Booser D, Qi Y, Coutant C, Shiang CY-H, Santarpia L,
Matsuoka J, Hortobagyi GN, Symmans WF, Holmes FA, O’Shaughnessy J,
Hellerstedt B, Pippen J, Andre F, Simon R, Pusztai L: Gene pathways
associated with prognosis and chemotherapy sensitivity in molecular
subtypes of breast cancer. J Natl Cancer Inst 2011, 103:264–272.
38. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa
LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess
KR, Symmans WF, Pusztai L: Evaluation of a 30-gene paclitaxel, fluorouracil,
doxorubicin, and cyclophosphamide chemotherapy response predictor
in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010,
16:5351–5361.
39. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T,
Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R,
Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N,
Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A,
O’Shaughnessy J, Hortobagyi GN, Symmans WF: A genomic predictor of
response and survival following taxane-anthracycline chemotherapy for
invasive breast cancer. JAMA 2011, 305:1873–1881.
40. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U,
Speed TP: Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostat Oxf Engl 2003, 4:249–264.
41. Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S,
Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS,
Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS: Supervised
risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol
2009, 27:1160–1167.
42. Palmer C, Diehn M, Alizadeh AA, Brown PO: Cell-type specific gene
expression profiles of leukocytes in human peripheral blood. BMC
Genomics 2006, 7:115.
43. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K,
Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM,
Weinberg RA, Mani SA: Core epithelial-to-mesenchymal transition interactome
gene-expression signature is associated with claudin-low and metaplastic
breast cancer subtypes. Proc Natl Acad Sci U S A 2010, 107:15449–15454.
44. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, Datto MB, Kelley
M, Mathey-Prevot B, Potti A, Nevins JR: A pathway-based classification of
human breast cancer. Proc Natl Acad Sci U S A 2010, 107:6994–6999.
45. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat M-L, Gyorki
DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, Fox SB, Yan M,
French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ: Aberrant
luminal progenitors as the candidate target population for basal tumor
development in BRCA1 mutation carriers. Nat Med 2009, 15:907–913.
46. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG,
Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A
multigene assay to predict recurrence of tamoxifen-treated, node-negative
breast cancer. N Engl J Med 2004, 351:2817–2826.47. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V,
Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F,
Gianni L, Symmans WF, Pusztai L: Molecular anatomy of breast cancer
stroma and its prognostic value in estrogen receptor-positive and
-negative cancers. J Clin Oncol 2010, 28:4316–4323.
48. Sabatier R, Finetti P, Mamessier E, Raynaud S, Cervera N, Lambaudie E,
Jacquemier J, Viens P, Birnbaum D, Bertucci F: Kinome expression profiling
and prognosis of basal breast cancers. Mol Cancer 2011, 10:86.
49. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C,
Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M: T-cell metagene
predicts a favorable prognosis in estrogen receptor-negative and
HER2-positive breast cancers. Breast Cancer Res 2009, 11:R15.
50. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C: An immune
response gene expression module identifies a good prognosis subtype
in estrogen receptor negative breast cancer. Genome Biol 2007, 8:R157.
51. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Wirapati P, Becette
V, André S, Piccart M, Campone M, Brain E, Macgrogan G, Petit T, Jassem J,
Bibeau F, Blot E, Bogaerts J, Aguet M, Bergh J, Iggo R, Delorenzi M: A
stroma-related gene signature predicts resistance to neoadjuvant
chemotherapy in breast cancer. Nat Med 2009, 15:68–74.
52. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, Knudsen ES:
RB-pathway disruption in breast cancer: differential association with
disease subtypes, disease-specific prognosis and therapeutic response.
Cell Cycle Georget Tex 2010, 9:4153–4163.
53. Adélaïde J, Finetti P, Bekhouche I, Repellini L, Geneix J, Sircoulomb F,
Charafe-Jauffret E, Cervera N, Desplans J, Parzy D, Schoenmakers E, Viens P,
Jacquemier J, Birnbaum D, Bertucci F, Chaffanet M: Integrated profiling of
basal and luminal breast cancers. Cancer Res 2007, 67:11565–11575.
54. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco
I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H,
Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA,
Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M,
Golub TA, Lander ES, Mellinghoff IK, et al.: Assessing the significance of
chromosomal aberrations in cancer: methodology and application to
glioma. Proc Natl Acad Sci U S A 2007, 104:20007–20012.
55. Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J,
Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM:
Comparative oncogenomics identifies breast tumors enriched in functional
tumor-initiating cells. Proc Natl Acad Sci 2011, 109:2778–2783.
56. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander
J, Troge J, Grubor V, Yoon S, Wigler M, Ye K, Børresen-Dale A-L, Naume B, Schlict-
ing E, Norton L, Hägerström T, Skoog L, Auer G, Månér S, Lundin P, Zetterberg
A: Novel patterns of genome rearrangement and their association with sur-
vival in breast cancer. Genome Res 2006, 16:1465–1479.
57. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM:
Reporting recommendations for tumor marker prognostic studies
(REMARK). J Natl Cancer Inst 2005, 97:1180–1184.
58. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V,
Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N,
Hortobagyi GN, Pusztai L, Symmans WF: Determination of oestrogen-receptor
status and ERBB2 status of breast carcinoma: a gene-expression profiling
study. Lancet Oncol 2007, 8:203–211.
59. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA: erbB-2 is
a potent oncogene when overexpressed in NIH/3 T3 cells. Science 1987,
237:178–182.
60. The Cancer Genome Atlas Network: Comprehensive molecular portraits of
human breast tumours. Nature 2012, 490:61–70.
61. Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield
ML, Cole MD: A core MYC gene expression signature is prominent in
basal-like breast cancer but only partially overlaps the core serum
response. PLoS One 2009, 4:e6693.
62. Bertucci F, Birnbaum D: [Genomics and clinical research for breast
cancer]. Médecine Sci MS 2012, 28 Spec No 1:14–18.
63. Bertucci F, Finetti P, Birnbaum D: Basal breast cancer: a complex and
deadly molecular subtype. Curr Mol Med 2012, 12:96–110.
doi:10.1186/1476-4598-13-228
Cite this article as: Sabatier et al.: Claudin-low breast cancers: clinical,
pathological, molecular and prognostic characterization. Molecular
Cancer 2014 13:228.
